David Shaw’s Axsome Therapeutics AXSM Stock Holding History

David Shaw’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.79M	Buy	+40,000	New	+$8.67M	﹤0.01%	1829
2025 Q1	–	Sell	-31,500	Closed	-$2.67M	–	4244
2024 Q4	$2.67M	Hold	31,500	–	–	﹤0.01%	2505
2024 Q3	$2.83M	Hold	31,500	–	–	﹤0.01%	2421
2024 Q2	$2.54M	Hold	31,500	–	–	﹤0.01%	2438
2024 Q1	$2.51M	Buy	+31,500	New	+$2.64M	﹤0.01%	2452
2021 Q3	–	Sell	-20,800	Closed	-$1.4M	–	4953
2021 Q2	$1.4M	Hold	20,800	–	–	﹤0.01%	3273
2021 Q1	$1.18M	Hold	20,800	–	–	﹤0.01%	2993
2020 Q4	$1.7M	Hold	20,800	–	–	﹤0.01%	2659
2020 Q3	$1.48M	Sell	20,800 -20,000	-49%	-$1.56M	﹤0.01%	2597
2020 Q2	$3.36M	Buy	40,800 +20,000	+96%	+$1.54M	﹤0.01%	1986
2020 Q1	$1.22M	Buy	+20,800	New	+$1.69M	﹤0.01%	2583

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

David Shaw's AXSM Position: Q2 2026 in Review

David Shaw increased its Axsome Therapeutics (AXSM) stake by 0.21% in Q2 2026, buying an estimated $279K and bringing the position to 604,753 shares worth $148M. The position accounts for 0.07% of the portfolio, ranked #296.

David Shaw first reported a position in AXSM in Q2 2019 and has held it in 23 quarters since. 502 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

David Shaw held 604,753 shares of Axsome Therapeutics worth $148M as of Q2 2026.
David Shaw bought 1,288 Axsome Therapeutics shares in Q2 2026, an estimated $279K.
Axsome Therapeutics made up 0.07% of David Shaw's portfolio in Q2 2026, its #296 holding.
David Shaw first reported a position in Axsome Therapeutics in Q2 2019 and has held it in 23 quarters since.
502 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.